VACCINE THERAPY FOR CANCER – FACT OR FICTION?

1 Coley WB. The treatment of malignant tumours by repeated inoculations of erysipolas; with a report of ten original cases. Am J Med Sci 1893; 105:487-511.

2 Nauts HC. Bacteria and Cancer – antagonisms and benefits. Cancer Surv 1989; 8:713-23.

3 Urban JL RC Burton Holland JM Mechanisms of syngeneic tumor-rejection. Susceptibility of host selected progressor variants to various immunological effector cells. J Exp Med 1982; 155:557-73.

4 Uyttenhove C J Maryanski Boon T. Escape of mouse mastocytome P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 1983; 157:1040-52.

5 Wortzel RD C Philipps Schreiber H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 1983; 304:165-7.

6 Hui K F Grosveld Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 1984; 311:750-2.

7 Wallich R N Bulbuc Hammerling GJ Abrogation of metastatic properties of tumour cells by de novo expression of H-2k antigens following H-2-gene transfection. Nature 1985; 315:301-5.

8 Haywood GR McKhann CF. Antigenic specificities on murine sarcoma cells. Reciprocal relationship between normal transplantation antigens (H-2) and tumor-specific immunogenicity. J Exp Med 1971; 133:1171-87.

9 Trowsdale J P Travers Bodmer W f Expression of HLAA,-B, and -C and beta 2-microglobulin antigens in human choriocarcinoma cell lines. J Exp Med 1980; 152:11s-7s.

10 Restifo NP F Esquivel Asher AL Defective presentation of endogenous antigen by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol 1991; 147:1453-9.

11 Torre-Amione G RD Beauchamp Koeppen H A highly immunogenic tumor transfected with a murine transforming growth factor type s1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87:1486-90.

12 Hahne M D Rimoldi Schroter M Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274:1363-6.

13 Ohashi PS S Oehen Buerki K Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991; 65:305-17.

14 Burkly LC D Lo Kanagawa O T-cell tolerance by clonal energy in transgenic mice with nonlymphoid expression of MHC class II I-E. Nature 1989; 342:564-6.

15 Staveley-O’Carroll K E Sotomayor Montgomery J Induction of antigen-specific T-cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95:1178-83.

16 Wick M P Dubey Koeppen H Antigenic cancer cells grow progressively in immune hosts without evidence for T-cell exhaustion or systemic anergy. J Exp Med 1997; 186:229-38.

17 Speiser DE R Miranda Zakarian A Self antigens expressed by solid tumors do not efficiently stimulate naive oractivated T-cells: Implications for immunotherapy. J Exp Med 1997; 186:645-53.

18 Mueller DL MK Jenkins Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T-cell antigen receptor occupancy. Ann Rev Immunol 1989; 7:445-80.

19 Schwartz RH. Acquisition of immunological selftolerance. Cell 1989; 57:1073-81.

20 Schwartz RH. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71:1065-8.

21 Broder S Waldmann TA. The suppressor-cell network in cancer (first of two parts). N Engl J Med 1978; 299:1281-4.

22 Mizoguchi H JJ O’Shea Longo DL Alternations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258:1795-8.

23 Alexander JP S Kudoh Melsop KA T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin-2 and express interleukin-2 receptors. Cancer Res 1993; 53:1380-7.

24 Finke JH AH Zea Stanley J Loss of T-cell receptor ζ chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53:5613-6.

25 Nakagomi H M Petersson Magnusson I Decreased expression of the signal-transducing ζ chains in tumorinfiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993; 53:5610-2.

26 Tartour E S Latour Mathiot C Variable expression of CD3-ζ chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 1995; 63:205-12.

27 Renner C S Ohnesorge Held G T-cells from patients with Hodgkin's disease have a defective T-cell receptor ζ chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 1996; 88:236-41.

28 Wolfel T M Hauer Schneider J A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269:1281-4.

29 Rubinfeld B P Robbins El-Gamil M Stabilization of s - catenin by genetic defects in melanoma cell lines. Science 1997; 275:1790-2.

30 Huang AYC PH Gulden Woods AS The immunodominant major histocompatability complex class 1-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 1996; 93:9730-5.

31van der Bruggen P, Traversari C, Chomez P A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-6.

32Chen Y-T, Stockert E, Chen Y Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci USA 1994; 91:1004-8.

33 Gaugler B van den Eynde B van der Bruggen P Human gene MAGE-3 codes for an antigen recognised on a melanoma by antologous cytolytic T lymphocytes. J Exp Med 1994; 179:921-30.

34 Topalian SL L Rivoltini Mancini M Human CD4+ Tcells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994; 91:9461-5.

35 Brichard V Van Pel A The tyrosinase gene codes for an antigen recognized by antologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178:489-95.

36 Cox AL J Skipper Chen Y Identification of a peptide recognised by five melanoma-specific human cytotoxic T-cell lines. Science 1994; 264:716-9.

37 Kawakami Y S Eliyahu Delgado CH Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91:6458-62.

38 Bos JL. Ras Oncogenes in human cancer: A review. Cancer Res 1989; 49:4682-9

39 Barbacid M. Ras genes. Ann Rev Biochem 1987; 56:779-827.

40 Jung S Human T lymphocytes recognise a peptide of single point-mutated Schluesener JH. , oncogenic ras proteins. J Exp Med 1991; 173:273-6.

41 Fossum B T Gedde-Dahl III Breivik J p21-ras peptidespecific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T-cells recognise a peptide corresponding to a common mutation (13 Gly . Asp). Int J Cancer 1994; 56:40-5.

42Gedde-Dahl III T, Spurkland A, Eriksen JA Memory Tcells of a patient with follicular thyroid carcinoma recognise peptides derived from mutated p21 ras (Gln . Leu 61). Int Immunol 1992; 4:1331-7.

43 Levine AJ J Momand Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351:453-6.

44 Hollstein M D Sidransky Vogelstein B P53 mutations in human cancers. Science 1991; 253:49-53.

45 Yanuck M DP Carbone Pendleton CD A mutant p53 tumour suppressor protein in a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 1993; 53:3257-61.

46 Noguchi Y Y-T Chen Old LJ. A mouse mutant p53 product recognised by CD4+ and CD8+ T-cells. Proc Natl Acad Sci USA 1994; 91:3171-5.

47 Roth J D Dittmer Rea D P53 as a target for cancer vaccines: Recombant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 1996; 93:4781-6.

48 Slamon DJ W Godolphin Jones LA Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12.

49 Press MF MC Pike Chazin VR Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerised image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53:4960-70.

50 Brossart P G Stuhler Flad T Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognised by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998; 58:732-6.

51 Katsumata M T Okudaira Samanta A Prevention of breast tumour development in vivo by downregulation of the p185-neu receptor. Nature Med 1995; 1:644-8.

52 Beasley RP LY Hwang Lin CC Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet 1981; 2:1129-33.

53 Larouze B G Saimot Lustbader ED Host response to hepatitis B infection in patients with primary hepatic carcinoma and their families: a case/control study in Senegal, West Africa. Lancet 1976; 2:534-8.

54 Brechot C M Hadchouel Scotto J Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state. Lancet 1981; 2:765-8.

55Chang M-H, Chen C-J, Lai M-S Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New Engl J Med 1997; 336:1855-9.

56 Ressing ME WJ Van Driel Celis E Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A 0201-restricted E7-encoded epitope. Cancer Res 1996; 56:582-8.

57de Gruijl TD, Bontkes HJ, Stukart MJ T-cell proliferative responses against human papiollomavirus type 16 E7 oncoprotein are most prominent in cervical intra-epithelial neoplasia patients with a persistent viral infection. J Gen Virol 1996; 77:2183-91.

58 Berd D HC Maguire McCue P Treatment of metatatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8:1858-67.

59 Mitchell MS J Kan-Mitchell Kempf RA Active specific immunotherapy for melanoma: Phase I trial of allogenic lysates and a novel adjuvant. Cancer Res 1988; 48:5883-93.

60 Tepper RI Mule JJ. Review: Experimental and clinical studies of cytokine gene-modified tumor cells. Human Gene Ther 1994; 5:153-64.

61 Dranoff G E Jaffee Lazenby A Vaccination with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90:3539-43.

62 Banchereau K Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.

63 Townsend SE Allison JP. Tumor rejection after direct costimulation of CD8+ T-cells by B7-transfected melanoma cells. Science 1993; 259:368-70.

64 Chen L S Ashe Brady WA Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71:1093-102.

65 Chen L P McGowan Ashe S Tumor immunogenicity determines the effect of B7 costimulation on T-cell-mediated tumor immunity. J Exp Med 1994; 179:523-32.

66 Boussiotis VA G Freeman Gray G B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993; 178:1753-63.

67 Hathcock KS G Laszlo Dickler HB Identification of an alterative CTLA-4 ligand costimulatory for T cell activation. Science 1993; 262:905-7.

68 Freeman GJ F Borriello Hodes RJ Uncovering of functional alternative CTLA-4 counter-receptor in B-7 deficient mice. Science 1993; 262:907-9.

69 Freeman GJ JG Gribben Boussiotis VA Cloning of B7-2: A CTLA-4 counter receptor that costimulates human T cell proliferation. Science 1993; 262:909-11.

70 Tanaka K H Hayashi Hamada C Expression of major histocompatability complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci USA 1986; 83:8723-7.

71 Plaksin D C Gelber Feldman M Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngenic H-2Kb gene. Proc Natl Acad Sci USA 1988; 85:4463-7.

72 Gelber C D Plaksin Vadai E Abolishment of metastasis formation by murine tumor cells transfected with ‘foreign’ H-2K genes. Cancer Res 1989; 49:2366-73.

73 Kim M R Herberman Gorelik E. Increased sensitivity to TNF-mediated cytotoxicity of B16 melanoma cells after H-2kb gene transfection. J Immunol 1993; 151:3467-77.

74 Ostrand-Rosenberg S A Thakur Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990; 144:4068-71.

75 Ostrand-Rosenberg S C Roby Clements VK Tumorspecific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class II genes or allogenic MHCclass I genes. Int J Cancer 1991; 48(Suppl 6):61-8.

76 Huang AYC P Golumbek Ahmadzadeh M Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264:961-5.

77 Marchand M P Weynants Rankin E Tumor regression in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63:883-5.

78 Rosenberg SA JC Yang Schwartzentruber DJ Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998; 4:321-7.

79 Aichele P K Brduscha-Riem Zinkernagel RM T-cell priming versus T-cell tolerance induced by synthetic peptides. J Exp Med 1995; 182:261-6.

80 Toes RE RJ Blom Offinga R Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 1996; 156:3911-8.

81 Lathe R MP Kieny Gerlinger P Tumor prevention and rejection with recombinant vaccinia. Nature 1987; 326:878-80.

82 Moss B GL Smith Gerin J l Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 1984; 311:67-9.

83 Bernards R A Destree McKenzie S Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA 1987; 84:6854-8.

84 Chen PW M Wang Bronte V Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 1996; 156:224-31.

85 Wang M V Bronte Chen PW Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995; 154:4685-92.

86 Tsang KY S Zaremba Nieroda CA Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunised with recombinant vaccinia – CEA vaccine. J Natl Cancer Inst 1995; 87:982-90.

87 Borysiewicz LK A Fiander Nimako M A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347:1523-7.

88 Hoiseth SK Stocker BAD. Aromatic-dependent salmonella typhimirium are non-virulent and effective as live vaccines. Nature 1981; 291:238-9.

89 Sadoff JC WR Ballou Baron LS Oral salmonella typhimirium vaccine expressing circumsporozoite protein protects against malaria. Science 1988; 240:336-8.

90 Stover CK VF de la Cruz Fuerst TR New use of BCG for recombinant vaccines. Nature 1991; 351:456-60.

91 Aldovini A Humoral Young RA. immune cell-mediated responses to live recombinant BCG-HIV vaccines. Nature 1991; 351:479-82.

92 Schafer R DA Portnoy Brassell SA Induction of a cellular immune response to a foreign antigen by a recombinant listeria monocytogenes vaccine. J Immunol 1992; 149:53-9.

93Pan Z-K, Ikonomidis G, Lazenby A A recombinant listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nature Med 1995; 1:471-7.

94Pan Z-K, Ikonomidis G, Pardoll D Regression of established tumours in mice mediated by the oral administration of a recombinant listeria monocytogenes vaccine. Cancer Res 1995; 55:4776-9.

95 Wolff JA RW Malone Williams P Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8.

96 Tang D M DeVit Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356:152-4.

97 Ulmer JB JJ Donelly Parker SE Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9.

98 Irvine KR RS Chamberlain Shulman EP Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997;89:1595-601.

99 Roz E DA Carson Parker SE Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994; 91:9519-23.

100 Fynan EF RG Webster Fuller DH DNA vaccines: protective immunization by parenteral, mucosal and genegun inoculations. Proc Natl Acad Sci USA 1993; 90:11478-82.

101 Nabel GJ EG Nabel Yang Z-Y Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90:11307-11.

102 Jones DH S Corris McDonald S Poly (DL-lactide-coglycolide)- encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997; 15:814-7.

103 Hersey P A Edwards Coates A Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Immunol Immunother 1987; 25:257-65.

104 McGee JM GH Lytle Malnar KF Melanoma tumor vaccine: five-year follow-up. J Surg Oncol 1991; 47:233-8.

105 Morton DL LJ Foshag Hoon DS Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216:463-82.

106 Bystryn JC. Clinical activity of a polyvalent melanoma antigen vaccine. Recent Results Cancer Res 1995; 139:337-48.

107 Batliwalla FM BA Bateman Serrano D A 15-year followup of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T-cell repertoire. Mol Med 1998; 4:783-94.

108 Wallace MK M Sivanandham Ditaranto K Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multiinstitutional trial. Ann Surg 1997; 226:198-206.

109 Palmer K J Moore Everard M Gene therapy with autologous, interleukin 2-secreting tumour cells in patients with malignant melanoma. Hum Gene Ther 1999; 10:1261-8.

110 Schreiber S E Kampgen Wagner E Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum Gene Ther 1999; 10:983-93.

111 Wang F E Bade Kuniyoshi C Phase I trial of a MART-1 peptide vaccine with incomplete Freund’s adjuvant for resected high-risk melanoma. Clin Cancer Res 1999; 5:2756-65.

112 Tsang KY S Zaremba Nieroda CA Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87:982-90.

113 Foon KA M Chakraborty John WJ Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995; 96:334-42.

114 McAneny D CA Ryan Beazley RM Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 1996; 3:495-500.

115 Conny RM MB Khazaeli Saleh MN Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999; 5:2330-7.

116 Lehner B P Schlag Liebrich W Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumour cell vaccine. Cancer Immunol Immunother 1990; 32:173-8.

117 Vermorken JB AM Claessen Van Tinteren H Active specific immunotherapy for stage I and stage III human colon cancer: a randomised trial. Lancet 1999; 353:345-50.

118 Van Driel WJ ME Ressing Kenter GG Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999; 35:946-52.

119 Itzkowitz SH EJ Bloom Kokal WA Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990; 66:1960-6.

120 Miles DW J Linehan Smith P et al E xpression of sialyl-Tn in gastic cancer: correlation with known prognostic factors. Br J Cancer 1995; 71:1074-6.

121 Kobayashi H T Terao Kawashima Y. Serum sialyl-Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992; 10:95-101.

122 Miles DW LC Happerfield Smith P Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br J Cancer 1994; 70:1272-5.

123 MacLean GD MA Reddish Koganty RR Immunisation of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993; 36:215-22.

124 Miles DW KE Towlson Graham R A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specificimmunotherapy of breast cancer. Br J Cancer 1996; 74:1292-6.

125 Murphy GP BA Tjoa Simmons SJ Phase II prostate cancer vaccine trial: report of a study, involving 37 patients with disease recurrence following primary treatment. Prostate 1999; 39:54-9.

126 Simons JW B Mikhak Chang JF Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumour cells engineered to a secrete granulocyte-macrophage colonystimulating factor using ex vivo gene transfer. Cancer Res 1999; 59:5160-8.

127 Slovin SF G Ragapatti Adluri S Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci USA 1999; 96:5710-5.

128 Dickler MN G Ragupathi Liu NX Immunogenicity of a fucosyl-GMI-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res 1999; 5:2773-9.

129 Bendandi M CD Gocke Kobrin CB Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5:1171-7.